| Literature DB >> 32714404 |
Fangzhou Liu1, Yuanbai Li1, Meng Li1, Jing Wang1, Yiying Zhang1, Yu Du1, Yang Yang1.
Abstract
OBJECTIVE: To investigate the pharmacological mechanism of the iridoid glycosides from Fructus Gardeniae in Jiangxi province by network pharmacology. To provide a valuable research strategy for the rational use and in-depth research and development of Fructus Gardeniae from Jiangxi.Entities:
Year: 2020 PMID: 32714404 PMCID: PMC7336235 DOI: 10.1155/2020/4062813
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The schematic illustration of the network pharmacology analysis.
Information of potential targets from characteristic high-content bioactive components group of Fructus Gardeniae from Jiangxi province in China.
| Molecule | OB (%) | DL | Target | Gene | UniProt ID | Probability |
|---|---|---|---|---|---|---|
| Geniposide | 14.64 | 0.44 | MX2 : AA81X2 : AA81microtubule-associated protein tau | MAPT | P10636 | 75.00 |
| 14.64 | 0.44 | Protein kinase C gamma type | PRKCG | P05129 | 24.00 | |
| 14.64 | 0.44 | Protein kinase C beta type | PRKCB | P05771 | 24.00 | |
| 14.64 | 0.44 | Protein kinase C alpha type | PRKCA | P17252 | 24.00 | |
| 14.64 | 0.44 | Protein kinase C theta type | PRKCQ | Q04759 | 24.00 | |
| 14.64 | 0.44 | Protein kinase C delta-type regulatory subunit | PRKCD | Q05655 | 24.00 | |
| 14.64 | 0.44 | Hypoxia-inducible factor 1-alpha | HIF1A | Q16665 | 24.00 | |
| 14.64 | 0.44 | Endothelial PAS domain-containing protein 1 | EPAS1 | Q99814 | 24.00 | |
| 14.64 | 0.44 | Bcl-2-like protein 1 | BCL2L1 | Q07817 | 18.00 | |
| 14.64 | 0.44 | Apoptosis regulator Bcl-2 | BCL2 | P10415 | 18.00 | |
| 14.64 | 0.44 | Bcl-2-like protein 2 | BCL2L2 | Q92843 | 18.00 | |
| 14.64 | 0.44 | Mu-type opioid receptor | OPRM1 | P35372 | 14.00 | |
| 14.64 | 0.44 | Delta-type opioid receptor | OPRD1 | P41143 | 14.00 | |
| 14.64 | 0.44 | Kappa-type opioid receptor | OPRK1 | P41145 | 14.00 | |
| 14.64 | 0.44 | Nociceptin receptor | OPRL1 | P41146 | 14.00 | |
|
| ||||||
| Gardenoside | 52.77 | 0.12 | Microtubule-associated protein tau | MAPT | P10636 | 68.00 |
| 52.77 | 0.12 | Protein kinase C gamma type | PRKCG | P05129 | 25.00 | |
| 52.77 | 0.12 | Protein kinase C beta type | PRKCB | P05771 | 25.00 | |
| 52.77 | 0.12 | Protein kinase C alpha type | PRKCA | P17252 | 25.00 | |
| 52.77 | 0.12 | Protein kinase C theta type | PRKCQ | Q04759 | 25.00 | |
| 52.77 | 0.12 | Protein kinase C delta-type regulatory subunit | PRKCD | Q05655 | 25.00 | |
| 52.77 | 0.12 | Hypoxia-inducible factor 1-alpha | HIF1A | Q16665 | 16.00 | |
| 52.77 | 0.12 | Endothelial PAS domain-containing protein 1 | EPAS1 | Q99814 | 16.00 | |
| 52.77 | 0.12 | Tyrosine-protein phosphatase nonreceptor type 2 | PTPN2 | P17706 | 16.00 | |
| 52.77 | 0.12 | Tyrosine-protein phosphatase nonreceptor type 1 | PTPN1 | P18031 | 16.00 | |
| 52.77 | 0.12 | Tyrosyl-DNA phosphodiesterase 1 | TDP1 | Q9NUW8 | 15.00 | |
| 52.77 | 0.12 | Mu-type opioid receptor | OPRM1 | P35372 | 14.00 | |
| 52.77 | 0.12 | Delta-type opioid receptor | OPRD1 | P41143 | 14.00 | |
| 52.77 | 0.12 | Kappa-type opioid receptor | OPRK1 | P41145 | 14.00 | |
| 52.77 | 0.12 | Nociceptin receptor | OPRL1 | P41146 | 14.00 | |
|
| ||||||
| Geniposidic acid | 19.59 | 0..41 | Microtubule-associated protein tau | MAPT | P10636 | 74.00 |
| 19.59 | 0..41 | Hypoxia-inducible factor 1-alpha | HIF1A | Q16665 | 29.00 | |
| 19.59 | 0..41 | Endothelial PAS domain-containing protein 1 | EPAS1 | Q99814 | 29.00 | |
| 19.59 | 0..41 | Protein kinase C gamma type | PRKCG | P05129 | 22.00 | |
| 19.59 | 0..41 | Protein kinase C beta type | PRKCB | P05771 | 22.00 | |
| 19.59 | 0..41 | Protein kinase C alpha type | PRKCA | P17252 | 22.00 | |
| 19.59 | 0..41 | Protein kinase C theta type | PRKCQ | Q04759 | 22.00 | |
| 19.59 | 0..41 | Protein kinase C delta-type regulatory subunit | PRKCD | Q05655 | 22.00 | |
| 19.59 | 0..41 | Tyrosyl-DNA phosphodiesterase 1 | TDP1 | Q9NUW8 | 21.00 | |
| 19.59 | 0..41 | Bcl-2-like protein 1 | BCL2L1 | Q07817 | 18.00 | |
| 19.59 | 0..41 | Apoptosis regulator Bcl-2 | BCL2 | P10415 | 18.00 | |
| 19.59 | 0..41 | Bcl-2-like protein 2 | BCL2L2 | Q92843 | 18.00 | |
| 19.59 | 0..41 | Sodium-dependent noradrenaline transporter | SLC6A2 | P23975 | 14.00 | |
| 19.59 | 0..41 | Sodium-dependent dopamine transporter | SLC6A3 | Q01959 | 14.00 | |
| 19.59 | 0..41 | Activation peptide fragment 1 | F2 | P00734 | 14.00 | |
|
| ||||||
| Genipin 1-gentiobioside | 45.58 | 0.83 | Microtubule-associated protein tau | MAPT | P10636 | 71.00 |
| 45.58 | 0.83 | Hypoxia-inducible factor 1-alpha | HIF1A | Q16665 | 31.00 | |
| 45.58 | 0.83 | Endothelial PAS domain-containing protein 1 | EPAS1 | Q99814 | 31.00 | |
| 45.58 | 0.83 | Tyrosine-protein phosphatase nonreceptor type 2 | PTPN2 | P17706 | 20.00 | |
| 45.58 | 0.83 | Tyrosine-protein phosphatase nonreceptor type 1 | PTPN1 | P18031 | 20.00 | |
| 45.58 | 0.83 | Transient receptor potential cation channel subfamily V member 1 | TRPV1 | Q8NER1 | 14.00 | |
| 45.58 | 0.83 | Activation peptide fragment 1 | F2 | P00734 | 13.00 | |
| 45.58 | 0.83 | Transient receptor potential cation channel subfamily V member 4 | TRPV4 | Q9HBA0 | 13.00 | |
| 45.58 | 0.83 | Transient receptor potential cation channel subfamily V member 2 | TRPV2 | Q9Y5S1 | 13.00 | |
| 45.58 | 0.83 | Tyrosyl-DNA phosphodiesterase 1 | TDP1 | Q9NUW8 | 11.00 | |
| 45.58 | 0.83 | D (1A) dopamine receptor | DRD1 | P21728 | 10.00 | |
| 45.58 | 0.83 | D (1B) dopamine receptor | DRD5 | P21918 | 10.00 | |
| 45.58 | 0.83 | Motilin receptor | MLNR | O43193 | 10.00 | |
| 45.58 | 0.83 | Growth hormone secretagogue receptor type 1 | GHSR | Q92847 | 10.00 | |
| 45.58 | 0.83 | D (2) dopamine receptor | DRD2 | P14416 | 9.00 | |
|
| ||||||
| Gardoside | — | — | Microtubule-associated protein tau | MAPT | P10636 | 86.00 |
| — | — | Hypoxia-inducible factor 1-alpha | HIF1A | Q16665 | 22.00 | |
| — | — | Endothelial PAS domain-containing protein 1 | EPAS1 | Q99814 | 22.00 | |
| — | — | Glycine receptor subunit alpha-1 | GLRA1 | P23415 | 19.00 | |
| — | — | Glycine receptor subunit alpha-2 | GLRA2 | P23416 | 19.00 | |
| — | — | Glycine receptor subunit alpha-3 | GLRA3 | O75311 | 19.00 | |
| — | — | Glycine receptor subunit beta | GLRB | P48167 | 19.00 | |
| — | — | Glycine receptor subunit alpha-4 | GLRA4 | Q5JXX5 | 19.00 | |
| — | — | Corticosteroid 11-beta-dehydrogenase isozyme 1 | HSD11B1 | P28845 | 12.00 | |
| — | — | Hydroxysteroid 11-beta-dehydrogenase 1-like protein | HSD11B1L | Q7Z5J1 | 12.00 | |
| — | — | Tyrosyl-DNA phosphodiesterase 1 | TDP1 | Q9NUW8 | 12.00 | |
| — | — | Protein kinase C gamma type | PRKCG | P05129 | 10.00 | |
| — | — | Protein kinase C beta type | PRKCB | P05771 | 10.00 | |
| — | — | Protein kinase C alpha type | PRKCA | P17252 | 10.00 | |
| — | — | Protein kinase C theta type | PRKCQ | Q04759 | 10.00 | |
|
| ||||||
| Shanzhiside | 117.77 | 0.10 | Microtubule-associated protein tau | MAPT | P10636 | 89.00 |
| 117.77 | 0.10 | Hypoxia-inducible factor 1-alpha | HIF1A | Q16665 | 19.00 | |
| 117.77 | 0.10 | Endothelial PAS domain-containing protein 1 | EPAS1 | Q99814 | 19.00 | |
| 117.77 | 0.10 | Tyrosyl-DNA phosphodiesterase 1 | TDP1 | Q9NUW8 | 14.00 | |
| 117.77 | 0.10 | Protein kinase C alpha type | PRKCA | P17252 | 14.00 | |
| 117.77 | 0.10 | Protein kinase C delta-type regulatory subunit | PRKCD | Q05655 | 14.00 | |
| 117.77 | 0.10 | Protein kinase C gamma type | PRKCG | P05129 | 14.00 | |
| 117.77 | 0.10 | Protein kinase C beta type | PRKCB | P05771 | 14.00 | |
| 117.77 | 0.10 | Protein kinase C theta type | PRKCQ | Q04759 | 14.00 | |
| 117.77 | 0.10 | Corticosteroid 11-beta-dehydrogenase isozyme 1 | HSD11B1 | P28845 | 14.00 | |
| 117.77 | 0.10 | Hydroxysteroid 11-beta-dehydrogenase 1-like protein | HSD11B1L | Q7Z5J1 | 14.00 | |
| 117.77 | 0.10 | Glycine receptor subunit alpha-1 | GLRA1 | P23415 | 10.00 | |
| 117.77 | 0.10 | Glycine receptor subunit alpha-2 | GLRA2 | P23416 | 10.00 | |
| 117.77 | 0.10 | Glycine receptor subunit alpha-3 | GLRA3 | O75311 | 10.00 | |
| 117.77 | 0.10 | Glycine receptor subunit beta | GLRB | P48167 | 10.00 | |
Figure 2The C-T-D network generated in this study. Yellow nodes represent the potential targets, the purple capsule-shaped nodes represent the candidate compounds, and the blue head-shaped nodes represent the related diseases, while the edges represent the interactions between them.
Figure 3GO enrichment of 36 target genes. The horizontal axis represents the categories of “biological process,” “cellular components,” and “molecular functions” in the GO of the target genes, while the vertical axis represents the significant enrichment counts of these terms.
Gene ontology term, biological process, direct (top 20).
| GO term |
| Count |
|---|---|---|
| Regulation of biological quality | 1.19 | 31 |
| Response to oxygen-containing compound | 6.99 | 23 |
| Response to organonitrogen compound | 1.16 | 19 |
| Response to nitrogen compound | 4.74 | 19 |
| System process | 1.03 | 23 |
| Response to stimulus | 1.44 | 34 |
| Nervous system process | 4.39 | 20 |
| Behavior | 5.52 | 16 |
| Anterograde transsynaptic signaling | 7.06 | 16 |
| Chemical synaptic transmission | 7.06 | 16 |
| Transsynaptic signaling | 8.08 | 16 |
| Multicellular organismal process | 8.74 | 32 |
| Response to organic substance | 8.89 | 25 |
| Synaptic signaling | 9.48 | 16 |
| Signaling | 1.59 | 30 |
| Cell communication | 1.75 | 30 |
| Cellular response to stimulus | 3.39 | 31 |
| Cellular response to oxygen-containing compound | 6.00 | 18 |
| Cell-cell signaling | 9.99 | 19 |
| Response to stress | 1.04 | 25 |
Gene ontology term, cellular component, direct (top 20).
| GO term |
| Count |
|---|---|---|
| Plasma membrane | 5.61 | 29 |
| Cell periphery | 9.05 | 29 |
| Plasma membrane part | 1.3 | 23 |
| Synapse part | 5.5 | 17 |
| Synaptic membrane | 5.9 | 14 |
| Neuron projection | 1.12 | 18 |
| Postsynapse | 1.68 | 15 |
| Membrane | 6.59 | 32 |
| Neuron part | 9.05 | 19 |
| Synapse | 2.89 | 17 |
| Plasma membrane region | 5.72 | 17 |
| Postsynaptic membrane | 8.24 | 12 |
| Membrane part | 3.92 | 28 |
| Plasma membrane-bounded cell projection | 4.77 | 19 |
| Cell projection part | 8.26 | 17 |
| Plasma membrane-bounded cell projection part | 8.26 | 17 |
| Cell projection | 8.95 | 19 |
| Integral component of plasma membrane | 2.79 | 16 |
| Cell part | 4.92 | 36 |
| Cell | 5.74 | 36 |
Gene ontology term, molecular function, direct (top 20).
| GO term |
| Count |
|---|---|---|
| Neurotransmitter receptor activity | 2.98 | 9 |
| Signaling receptor activity | 1.05 | 17 |
| Molecular transducer activity | 1.64 | 17 |
| Transmembrane signaling receptor activity | 2.03 | 16 |
| Channel activity | 4.08 | 10 |
| Extracellularly glycine-gated chloride channel activity | 4.13 | 4 |
| Extracellularly glycine-gated ion channel activity | 4.13 | 4 |
| Passive transmembrane transporter activity | 4.19 | 10 |
| Protein kinase C activity | 1.33 | 5 |
| Inhibitory extracellular ligand-gated ion channel activity | 2.06 | 4 |
| Transmembrane transporter activity | 2.1 | 12 |
| Inorganic molecular entity transmembrane transporter activity | 2.1 | 11 |
| Ion transmembrane transporter activity | 5.42 | 11 |
| Ion channel activity | 6.29 | 9 |
| Transporter activity | 6.4 | 12 |
| Binding | 7.45 | 32 |
| Substrate-specific channel activity | 8.01 | 9 |
| Extracellular ligand-gated ion channel activity | 1.31 | 6 |
| Excitatory extracellular ligand-gated ion channel activity | 3.59 | 5 |
| Chloride transmembrane transporter activity | 4.64 | 6 |
Classification and information on target components-related pathways, direct (top 20).
| Classification | Pathway |
| Annotated genes count |
|---|---|---|---|
| Signaling molecules and interaction | Neuroactive ligand-receptor interaction | 4.25 | 15 |
| Signal transduction | GPCR downstream signaling | 1.17 | 15 |
| Signaling by GPCR | 6.64 | 15 | |
| Class A/1 (rhodopsin-like receptors) | 9.8 | 10 | |
| GPCR ligand-binding | 2.95 | 10 | |
| Peptide ligand-binding receptors | 1.98 | 7 | |
| G alpha ( | 5.01 | 5 | |
| Dopamine receptors | 5.3 | 3 | |
| HIF-1 signaling pathway | 2.24 | 5 | |
| Organismal systems | Inflammatory mediator regulation of TRP channels | 1.38 | 8 |
| Dopaminergic synapse | 1.47 | 7 | |
| Human diseases | Amphetamine addiction | 3.01 | 5 |
| EGFR tyrosine kinase inhibitor resistance | 6.47 | 5 | |
| Morphine addiction | 1.32 | 5 | |
| Cellular processes | Gap junction | 1.12 | 5 |
| Transport of small molecules | Ion channel transport | 7.04 | 8 |
| Ligand-gated ion channel transport | 1.95 | 5 | |
| Transmembrane transport of small molecules | 1.44 | 10 | |
| Hemostasis | Platelet activation, signaling, and aggregation | 3.32 | 7 |
| Disinhibition of SNARE formation | 5.3 | 3 |
Figure 4The main chemicals-targets-signaling pathway (C-T-P) of Fructus Gardeniae from Jiangxi province. Target genes are shown with blue circular nodes, green diamond nodes represent the characteristic high-content bioactive components of Fructus Gardeniae from Jiangxi province, and purple V nodes are signaling pathways.
Figure 5Pathway enrichment point diagram of 36 target genes. The vertical axis represents the pathway name, the horizontal axis represents the rich factor, the size of the dot indicates the number of genes expressed in the pathway, and the color of the dot corresponds to the different P value range.